5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Acute O
Changes O
in O
Lung O
Compliance O
: O
Infants O
receiving O
SURFAXIN O
should O
receive O
frequent O
clinical O
assessments O
so O
that O
oxygen O
and O
ventilatory O
support O
can O
be O
modified O
to O
respond O
to O
changes O
in O
respiratory O
status O
. O

( O
5.1 O
) O
* O
Administration-Related O
Adverse O
Reactions O
: O
If O
adverse O
reactions O
including O
bradycardia O
, O
oxygen O
desaturation O
, O
reflux O
of O
SURFAXIN O
into O
the O
endotracheal O
tube O
( O
ETT O
) O
, O
and O
airway/ETT O
obstruction O
occur O
during O
administration O
of O
SURFAXIN O
, O
dosing O
should O
be O
interrupted O
and O
the O
infant O
's O
clinical O
condition O
assessed O
and O
stabilized O
. O

Suctioning O
of O
the O
ETT O
or O
reintubation O
may O
be O
required O
if O
airway O
obstruction O
persists O
or O
is O
severe O
. O

( O
5.2 O
) O
* O
Increased O
Serious O
Adverse O
Reactions O
in O
Adults O
with O
Acute O
Respiratory O
Distress O
Syndrome O
( O
ARDS O
) O
: O
Adults O
with O
ARDS O
who O
received O
lucinactant O
via O
segmental O
bronchoscopic O
lavage O
had O
an O
increased O
incidence O
of O
death O
, O
multi-organ O
failure O
, O
sepsis O
, O
anoxic O
encephalopathy O
, O
renal O
failure O
, O
hypoxia O
, O
pneumothorax O
, O
hypotension O
, O
and O
pulmonary O
embolism O
. O

SURFAXIN O
is O
not O
indicated O
for O
use O
in O
ARDS O
. O

( O
5.3 O
) O
5.1 O
Acute O
Changes O
in O
Lung O
Compliance O
Administration O
of O
exogenous O
surfactants O
, O
including O
SURFAXIN O
, O
can O
rapidly O
affect O
lung O
compliance O
and O
oxygenation O
. O

SURFAXIN O
should O
be O
administered O
only O
by O
clinicians O
trained O
and O
experienced O
in O
the O
resuscitation O
, O
intubation O
, O
stabilization O
, O
and O
ventilatory O
management O
of O
premature B-Not_AE_Candidate
infants I-Not_AE_Candidate
in O
a O
clinical O
setting O
with O
the O
capacity O
to O
care O
for O
critically O
ill O
neonates O
. O

Infants O
receiving O
SURFAXIN O
should O
receive O
frequent O
clinical O
assessments O
so O
that O
oxygen O
and O
ventilatory O
support O
can O
be O
modified O
to O
respond O
to O
changes O
in O
respiratory O
status O
. O

5.2 O
Administration B-NonOSE_AE
- I-NonOSE_AE
Related I-NonOSE_AE
Adverse I-NonOSE_AE
Reactions I-NonOSE_AE
Frequently O
occurring O
adverse O
reactions O
related O
to O
the O
administration O
of O
SURFAXIN O
include O
bradycardia B-OSE_Labeled_AE
, O
oxygen B-OSE_Labeled_AE
desaturation I-OSE_Labeled_AE
, O
reflux B-OSE_Labeled_AE
of I-OSE_Labeled_AE
drug I-OSE_Labeled_AE
into I-OSE_Labeled_AE
the I-OSE_Labeled_AE
endotracheal I-OSE_Labeled_AE
tube I-OSE_Labeled_AE
( O
ETT O
) O
, O
and O
airway B-OSE_Labeled_AE
/ETT O
obstruction I-OSE_Labeled_AE
. O

If O
any O
of O
these O
events O
occur O
, O
dosing O
with O
SURFAXIN O
should O
be O
interrupted O
and O
the O
infant O
's O
clinical O
condition O
assessed O
and O
stabilized O
. O

Suctioning O
of O
the O
ETT O
or O
reintubation O
may O
be O
required O
if O
airway B-NonOSE_AE
obstruction I-NonOSE_AE
persists O
or O
is O
severe O
. O

After O
the O
patient O
is O
stable O
, O
dosing O
may O
proceed O
with O
appropriate O
monitoring O
. O

5.3 O
Increased O
Serious O
Adverse O
Reactions O
in O
Adults O
with O
ARDS O
In O
a O
two-part O
clinical O
trial O
in O
adult O
patients O
with O
ARDS B-Not_AE_Candidate
, O
compared O
to O
standard O
of O
care O
, O
patients O
who O
received O
lucinactant O
via O
segmental O
bronchoscopic O
lavage O
had O
an O
increased O
incidence O
of O
death B-NonOSE_AE
, O
multi B-NonOSE_AE
- I-NonOSE_AE
organ I-NonOSE_AE
failure I-NonOSE_AE
, O
sepsis B-NonOSE_AE
, O
anoxic B-NonOSE_AE
encephalopathy I-NonOSE_AE
, O
renal B-NonOSE_AE
failure I-NonOSE_AE
, O
hypoxia B-NonOSE_AE
, O
pneumothorax B-NonOSE_AE
, O
hypotension B-NonOSE_AE
, O
and O
pulmonary B-NonOSE_AE
embolism I-NonOSE_AE
. O

SURFAXIN O
is O
not O
indicated O
for O
use O
in O
the O
treatment O
of O
ARDS O
. O

